Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Phenotypic heterogeneity and remodeling drive resistance to venetoclax treatment in acute myeloid leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

KFKen FurudateZLZongrui LiMLMinggao Liang

Discussion

Loading...

Member takes

Overview

Integrative analysis reveals phenotypic heterogeneity drives resistance to venetoclax in acute myeloid leukemia, indicating a need for targeted treatments.

Key Points

  • Resistance to venetoclax is associated with phenotypic heterogeneity and enriched mature acute myeloid leukemia cells, complicating treatment efficacy.
  • K-means clustering of samples identified groups based on mutations and response to decitabine and venetoclax, with significant implications for therapy outcomes.
  • Integrative analysis using single-cell RNA sequencing revealed critical changes in stem/progenitor cells and cellular composition related to treatment response.
  • Findings highlight the need for therapies that address diverse cell types, suggesting phenotypic monitoring could improve patient outcomes.

Cite This Study

Furudate et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dc57https://doi.org/10.1182/blood-2025-222
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Single-cell transcriptomic insights into venetoclax response and resistance in secondary AML evolving from MDS2025
  2. 2Single-cell insights into acute myeloid leukemia treated with venetoclax-based therapy2025
  3. 3Venetoclax dosages, BH3 profiling, and bcl-2 expression predict response to azacitidine + venetoclax regimen in first line AML not eligible to intensive chemotherapy: First results of venetacible study2025
  4. 4Mechanistic dissection of venetoclax sensitivity in AML through single-molecule BCL2 protein complex profiling and mutation-specific apoptotic rewiring2025 · 1 citations
  5. 5Data from Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study2025